BACKGROUND: There is a lack of data on idiopathic epilepsy (IE) in Border Collies (BCs) in the veterinary literature. HYPOTHESIS: Genetic epilepsy occurs in BCs and is frequently characterized by a severe clinical course and poor response to medical treatment. ANIMALS: Forty-nine BCs diagnosed with IE. METHODS: Medical records, seizure data, treatment data, and pedigree information of affected dogs were collected. Cases were classified phenotypically as affected or not affected; mild, moderate, or severe clinical course; active epilepsy (AE) or remission; and drug resistant or not drug resistant. RESULTS: Clinical manifestations were classified as having a moderate (33%) or severe clinical course (49%), characterized by a high prevalence of cluster seizures and status epilepticus. Survival time was significantly decreased in dogs < 2 years of age at seizure onset, and in dogs with a severe clinical course. Drug resistance was apparent in 71% of 24 dogs treated with > 2 antiepileptic drugs. The epilepsy remission rate was 18%. Median age at onset was significantly higher and initial seizure frequency was significantly lower in dogs with remission compared with dogs with AE. Pedigree analyses indicated a strong genetic founder effect in the appearance of epilepsy, resembling autosomal recessive inheritance. CONCLUSION AND CLINICAL IMPORTANCE: The present study confirms the occurrence of genetically mediated epilepsy with a frequent severe clinical course and drug resistance in BCs. The results provide information about the long-term prognosis of IE in BCs for veterinarians and concerned owners, and may benefit breeders as well.
BACKGROUND: There is a lack of data on idiopathic epilepsy (IE) in Border Collies (BCs) in the veterinary literature. HYPOTHESIS: Genetic epilepsy occurs in BCs and is frequently characterized by a severe clinical course and poor response to medical treatment. ANIMALS: Forty-nine BCs diagnosed with IE. METHODS: Medical records, seizure data, treatment data, and pedigree information of affected dogs were collected. Cases were classified phenotypically as affected or not affected; mild, moderate, or severe clinical course; active epilepsy (AE) or remission; and drug resistant or not drug resistant. RESULTS: Clinical manifestations were classified as having a moderate (33%) or severe clinical course (49%), characterized by a high prevalence of cluster seizures and status epilepticus. Survival time was significantly decreased in dogs < 2 years of age at seizure onset, and in dogs with a severe clinical course. Drug resistance was apparent in 71% of 24 dogs treated with > 2 antiepileptic drugs. The epilepsy remission rate was 18%. Median age at onset was significantly higher and initial seizure frequency was significantly lower in dogs with remission compared with dogs with AE. Pedigree analyses indicated a strong genetic founder effect in the appearance of epilepsy, resembling autosomal recessive inheritance. CONCLUSION AND CLINICAL IMPORTANCE: The present study confirms the occurrence of genetically mediated epilepsy with a frequent severe clinical course and drug resistance in BCs. The results provide information about the long-term prognosis of IE in BCs for veterinarians and concerned owners, and may benefit breeders as well.
Authors: Koen M Santifort; Elise Bertijn; Sofie F M Bhatti; Peter Leegwater; Andrea Fischer; Paul J J Mandigers Journal: Front Vet Sci Date: 2022-05-12
Authors: Eija H Seppälä; Lotta L E Koskinen; Christina H Gulløv; Päivi Jokinen; Peter Karlskov-Mortensen; Luciana Bergamasco; Izabella Baranowska Körberg; Sigitas Cizinauskas; Anita M Oberbauer; Mette Berendt; Merete Fredholm; Hannes Lohi Journal: PLoS One Date: 2012-03-23 Impact factor: 3.240
Authors: Luisa De Risio; Sofie Bhatti; Karen Muñana; Jacques Penderis; Veronika Stein; Andrea Tipold; Mette Berendt; Robyn Farqhuar; Andrea Fischer; Sam Long; Paul J J Mandigers; Kaspar Matiasek; Rowena M A Packer; Akos Pakozdy; Ned Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Martí Pumarola Batlle; Clare Rusbridge; Holger A Volk Journal: BMC Vet Res Date: 2015-08-28 Impact factor: 2.741
Authors: Velia-Isabel Hülsmeyer; Andrea Fischer; Paul J J Mandigers; Luisa DeRisio; Mette Berendt; Clare Rusbridge; Sofie F M Bhatti; Akos Pakozdy; Edward E Patterson; Simon Platt; Rowena M A Packer; Holger A Volk Journal: BMC Vet Res Date: 2015-08-28 Impact factor: 2.741
Authors: Sofie F M Bhatti; Luisa De Risio; Karen Muñana; Jacques Penderis; Veronika M Stein; Andrea Tipold; Mette Berendt; Robyn G Farquhar; Andrea Fischer; Sam Long; Wolfgang Löscher; Paul J J Mandigers; Kaspar Matiasek; Akos Pakozdy; Edward E Patterson; Simon Platt; Michael Podell; Heidrun Potschka; Clare Rusbridge; Holger A Volk Journal: BMC Vet Res Date: 2015-08-28 Impact factor: 2.741
Authors: Heidrun Potschka; Andrea Fischer; Wolfgang Löscher; Ned Patterson; Sofie Bhatti; Mette Berendt; Luisa De Risio; Robyn Farquhar; Sam Long; Paul Mandigers; Kaspar Matiasek; Karen Muñana; Akos Pakozdy; Jacques Penderis; Simon Platt; Michael Podell; Clare Rusbridge; Veronika Stein; Andrea Tipold; Holger A Volk Journal: BMC Vet Res Date: 2015-08-28 Impact factor: 2.741
Authors: Mette Berendt; Robyn G Farquhar; Paul J J Mandigers; Akos Pakozdy; Sofie F M Bhatti; Luisa De Risio; Andrea Fischer; Sam Long; Kaspar Matiasek; Karen Muñana; Edward E Patterson; Jacques Penderis; Simon Platt; Michael Podell; Heidrun Potschka; Martí Batlle Pumarola; Clare Rusbridge; Veronika M Stein; Andrea Tipold; Holger A Volk Journal: BMC Vet Res Date: 2015-08-28 Impact factor: 2.741